According to our hypothesis, factor Xa inhibition through LMWHs or DOACs could counteract the TF-mediated overexpression of hypoxia-related proteins and lead to detectable MR-morphological changes in GBM relapse. The gene discussed is TF; the disease is glioblastoma.